Your browser doesn't support javascript.
loading
Statistical analysis plan for the biomarker-guided intervention to prevent acute kidney injury after major surgery (BigpAK-2) study: An international randomised controlled multicentre trial.
von Groote, Thilo; Danzer, Moritz Fabian; Meersch, Melanie; Zarbock, Alexander; Gerß, Joachim.
Afiliación
  • von Groote T; Department of Anesthesiology, Intensive Care and Pain Medicine University, Hospital Münster, Münster, Germany.
  • Danzer MF; Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany.
  • Meersch M; Department of Anesthesiology, Intensive Care and Pain Medicine University, Hospital Münster, Münster, Germany.
  • Zarbock A; Department of Anesthesiology, Intensive Care and Pain Medicine University, Hospital Münster, Münster, Germany.
  • Gerß J; Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany.
Crit Care Resusc ; 26(2): 80-86, 2024 Jun.
Article en En | MEDLINE | ID: mdl-39072240
ABSTRACT

Objective:

This article describes the statistical analysis plan for the Biomarker-guided intervention to prevent AKI after major surgery (BigpAK-2) trial.

Design:

Adaptive trial design with an interim analysis after enrolment of 618 evaluable patients.

Setting:

The BigpAK.-2 trial is an international, prospective, randomised controlled multicentre study.

Participants:

The BigpAK-2 study enrols patients after major surgery who are admitted to the intensive care or high dependency unit and are at high-risk for postoperative AKI as identified by urinary biomarkers (tissue inhibitor of metalloproteinases-2 and insulin-like growth factor binding protein 7 ([TIMP-2]∗[IGFBP7]) will be enrolled. Intervention Patients are randomly and evenly allocated to standard of care (control) group or the implementation of a nephroprotective care bundle (intervention group), as recommended by the Kidney Disease Improving Global Outcomes (KDIGO) guidelines. The KDIGO care bundle recommends discontinuation of nephrotoxic agents if possible, ensuring adequate volume status and perfusion pressure, considering functional haemodynamic monitoring, regular monitoring of serum creatinine and urine output, avoiding hyperglycemia, and considering alternatives to radiocontrast procedures when possible.

Results:

The BigpAK-2 study investigates whether the biomarker-gudied implementation of the KDIGO care bundle reduces the incidence of moderate or severe AKI (stage 2 or 3), according to the KDIGO 2012 criteria, within 72 h after surgery.

Conclusion:

AKI is a common and often severe complication after major surgery. As no specific treatments exist, prevention of AKI is of high importance. The BigpAK-2 study investigates a promising approach to prevent AKI after major surgery. Trial registration The trial was registered prior to start at clinicaltrials.gov; NCT04647396.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Crit Care Resusc Asunto de la revista: TERAPIA INTENSIVA Año: 2024 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Crit Care Resusc Asunto de la revista: TERAPIA INTENSIVA Año: 2024 Tipo del documento: Article País de afiliación: Alemania